Smoking, vaping linked to higher risk of severe COVID-19 complications, including death

Innovation
Jul.27.2022

People who reported smoking or vaping prior to their hospitalization for COVID-19 were more likely than their counterparts who did not smoke or vape to experience severe complications, including death, from the SARS-CoV-2 infection. The findings are from a new study based on data from the American Heart Association's COVID-19 CVD Registry and published in PLOS ONE.

Smoking, vaping linked to higher risk of severe COVID-19 complications, including death

Researchers examined data on people over 18 years of age who were hospitalized with COVID-19 in 107 registry-participating hospitals across the nation between January 2020 to March 2021. Smoking status was self-reported and people were classified as smoking if they reported currently using either traditional, combustible cigarettes or e-cigarette products, with no distinction between the two and no information on duration of smoking or former smoking status. For the final analysis, records were selected for 4,086 people with a 1:2 ratio of people who smoked (1,362) to people who did not smoke (2,724), with the two groups matched for no statistically significant difference in age, sex, race, medical history or medication.

 

The study findings indicate smoking or vaping are associated with more severe COVID-19 independent of age, sex, race or medical history:

  • People who reported smoking were 45% more likely to die and 39% more likely to receive mechanical ventilation when compared with those who did not smoke.
  • Although the excessive risk due to smoking was independent of medical history and medication use, smoking was a stronger risk factor for death in people between 18-59 years of age and those who were white or had obesity.

"In general, people who smoke or vape tend to have a higher prevalence of other health conditions and risk factors that could play a role in how they are impacted by COVID-19. However, the robust and significant increase in the risk of severe COVID-19 seen in our study, independent of medical history and medication use and particularly among young individuals, underscores the urgent need for extensive public health interventions such as anti-smoking campaigns and increased access to cessation therapy, especially in the age of COVID," said the study's senior author, Aruni Bhatnagar, Ph.D., FAHA, a professor of medicine, biochemistry and molecular biology at the University of Louisville in Louisville, Kentucky. "These findings provide the clearest evidence to date that people who smoke or vape have a higher risk of developing severe COVID-19 and dying as a result of SARS-CoV-2 infection."

 

Bhatnagar is co-director of the American Heart Association's Tobacco Center for Regulatory Science which supported the study in part with funding from the U. S. National Institutes of Health and the Food and Drug Administration research grants.

 

"We established the COVID-19 CVD Registry early on in the pandemic to better understand the link between COVID-19 and cardiovascular disease, specifically, to identify increased risk to help inform the diagnosis and care of people who are at highest risk for complications," said Sandeep R. Das, M.D., M.P.H., M.B.A., FAHA, co-chair of the steering committee for the American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines and director for Quality and Value in the Cardiology Division at UT Southwestern Medical Center in Dallas, Texas. "The findings of this study deliver on that goal and provide invaluable information individuals and their healthcare teams."

 

The American Heart Association launched the registry in 2020 to gather data specific to all patients hospitalized with COVID-19 as part of the Get With The Guidelines quality improvement program. Registry participation was offered at no cost to all U.S. hospitals caring for adults with active COVID-19 and with the infrastructure to support accurate data collection. More than 160 hospitals provided data on more than 79,000 patient records between 2020 and June 2022.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Tobacco-Free Kids Condemns PMI for Marketing Zyn to Youth via F1 Sponsorship
Tobacco-Free Kids Condemns PMI for Marketing Zyn to Youth via F1 Sponsorship
Yolonda C. Richardson, President and CEO of the Campaign for Tobacco-Free Kids, issued a statement on December 10, 2025, condemning Philip Morris International (PMI) for partnering with Ferrari to promote Zyn nicotine pouches on Formula 1 cars. She said PMI’s claim that the sponsorship targets adults is misleading, as F1’s audience has become increasingly young—with over 4 million children aged 8–12 now following the sport.
Dec.12 by 2FIRSTS.ai
Bradford meeting told rising cannabis-vape use is a “threat to the younger generation”
Bradford meeting told rising cannabis-vape use is a “threat to the younger generation”
A licensing meeting in Bradford was told that the rising use of cannabis vapes is a “threat to the younger generation”. E-cigarettes containing THC are illegal for recreational purposes but have been found on sale in the district.
Dec.31 by 2FIRSTS.ai
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.
Dec.22 by 2FIRSTS.ai
NSW Landlords Could Face Jail or $165,000 Fine for Allowing Illegal Vape and Tobacco Sales
NSW Landlords Could Face Jail or $165,000 Fine for Allowing Illegal Vape and Tobacco Sales
According to The Guardian, landlords in New South Wales who knowingly allow tenants to sell illicit tobacco or illegal vapes could face fines of up to AUD 165,000, a year in prison, or both. The new offences are part of the state government’s broader crackdown on Australia’s growing black market for cigarettes and vaping products.
Nov.12 by 2FIRSTS.ai
AIR Acquires Germany’s NameLess to Expand Global Presence in Flavored Hookah Market
AIR Acquires Germany’s NameLess to Expand Global Presence in Flavored Hookah Market
AIR Limited, the Dubai-based global leader in hookah and advanced inhalation technologies, announced the acquisition of NameLess, one of Germany’s most recognized brands for premium flavored hookah products.
Dec.11 by 2FIRSTS.ai
U.S. vape firms appeal Mississippi synthetic-nicotine ban, citing FDA authority preemption
U.S. vape firms appeal Mississippi synthetic-nicotine ban, citing FDA authority preemption
A coalition of U.S. vape industry groups has appealed a Mississippi law banning the sale of e-cigarette products containing synthetic nicotine, arguing the statute effectively conditions sales on FDA authorization and unlawfully encroaches on federal regulatory authority. The law took effect in July 2025 and has already begun to be enforced.
Dec.17 by 2FIRSTS.ai